CT26-hCD24

PDFを取得

Strain Information

表現型データ

image.png

Figure 1. Expression of human CD24 on CT26-hCD24 cells was confirmed by flow cytometry.  

CT26-hCD24 cells and wild type CT26 cells were stained with species-specific anti- CD24 antibodies.  FACS analysis shows that human CD24 but not mouse CD24 was exclusively detectable on CT26-hCD24 cells.

image.png

Figure 2. In vivo tumor growth curves in humanized CT26-hCD24 syngeneic model.

BALB/c mice were subcutaneously injected 1×106 CT26-hCD24 cells compared with wild type CT26 cells as control.  Tumor growth was monitored by measuring tumor size from day 5 after subcutaneous implantation.

Data shows that there were no significant differences between CT26-hCD24 cells and wild type CT26 cells in either tumorigenicity or tumor growth.

image.png

Figure 3. FACS analysis of CD24 expression on tumor cells derived from humanized CT26-hCD24 syngeneic model with species-specific anti-CD24 antibodies.  

Data shows that human CD24 knock-in tumor exclusively express human CD24 but not mouse CD24.


関連の系統

あなたも好きかも

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

詳細
Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

詳細